1. Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance

   • Bryan Dowd
   • John A. Nyman

   Commentary 08 March 2019 Pages: 743 - 744

2. Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges

   • David Thesmar
   • David Sraer
   • Paul Greenberg

   Leading Article Open access 08 March 2019 Pages: 745 - 752

3. Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Joanna Picot
   • Neelam Kalita
   • Keith Cooper

   Review Article 17 October 2018 Pages: 753 - 762

   

4. Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Sarah Davis
   • Rachid Rafia
   • Munira Essat

   Review Article 22 October 2018 Pages: 763 - 775

5. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

   • Dongzhe Hong
   • Lei Si
   • Lizheng Shi

   Systematic Review 11 March 2019 Pages: 777 - 818

   

6. Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial

   • Fuxiao Li
   • Xiang Li
   • Yang Ke

   Original Research article 27 February 2019 Pages: 819 - 827

   

7. A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis

   • Devin Incerti
   • Jeffrey R. Curtis
   • Jeroen P. Jansen

   Original Research Article 09 February 2019 Pages: 829 - 843

   

8. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden

   • Santiago Zuluaga-Sanchez
   • Megan Teynor
   • Andrew Lloyd

   Original Research Article Open access 04 February 2019 Pages: 845 - 865

   

9. Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study

   • José Leal
   • Stefania Manetti
   • James Buchanan

   Correction Open access 05 March 2019 Pages: 867 - 867

10. Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    • Hema Mistry
    • Chidozie Nduka
    • James Mason

    Correction Open access 19 February 2019 Pages: 869 - 869